Graph shows 'Total claims with manufacturer coupons, %' from Oct 2017 to Sep 2019. The 'Candidate hop products' line starts low, peaks at ~24% in early 2019, then declines. 'Comparator products' gradually decrease from ~10% to ~6%.
For #biologic drugs nearing biosimilar competition, use of manufacturer coupons for new product line extensions increased and offset a greater share of patient costs than earlier products, indicating coupon programs may facilitate product hopping.
ja.ma/3NuApRu